Intarcia Therapeutics, Inc.

93 articles with Intarcia Therapeutics, Inc.

• 

  For Second Time, FDA Rejects Intarcia's Diabetes Implant

  3/11/2020

  In a statement issued to the Boston Business Journal, Intarcia expressed both disappointment and a determination to get an approval for ITCA 650.

• Intarcia Therapeutics Provides Regulatory Update - FDA Accepts Resubmitted New Drug Application For ITCA 650

  10/8/2019

  Intarcia Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's resubmission of its new drug application (NDA) for ITCA 650 (exenatide implant), for the treatment of type 2 diabetes mellitus.

• Numab Announces Entry into a License Agreement With Intarcia for Anti-Inflammatory ND016

  3/5/2019

  Numab Therapeutics AG today announced that Intarcia Therapeutics Inc. has executed its option to in-license ND016, being developed for the treatment of autoimmune disorders.

• Intarcia Provides 2019 Corporate Update

  12/18/2018

   Intarcia Therapeutics Inc. today provided an update on the company's progress in 2018 and trajectory for advancement in 2019.

• 

  Bay State is Home to Four Biotech Unicorns

  8/17/2018

  When people hear the word “unicorn” they may think of the mythical horse with a polished horn protruding from its brow. But in the world of investing, the term unicorn refers to a startup company worth more than $1 billion.

• Intarcia Appoints Thane Wettig as Chief Marketing Officer and Metabolic Franchise Head

  7/3/2018

  Wettig Brings Strong Background in Diabetes and Metabolic Diseases from Leading Global Diabetes Company

• 

  Foresite Capital Launches New Venture Capital Fund Worth $668 Million

  5/3/2018

  Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
• 

  Digital Health Movement Continues to Grow, as Do Concerns Over Privacy

  5/2/2018

  Getting patients to adhere to long-term treatments can be difficult. There are a number of new therapies that will monitor whether or not patients are sticking to their regimen.
• 

  Is There a Biotech Bubble Brewing in Boston?

  3/21/2018

  Billions of dollars are being invested in Boston-based life science companies.
• 

  Boston's Intarcia Pink Slips 60 Employees, Terminates Two Late-Stage Trials

  2/5/2018

  A tipster told BioSpace that the layoffs were initially announced by Intarcia CEO Kurt Graves on Jan. 31.
• 

  Can 2018 Possibly Rival 2017's Biotechs Record Venture Capital Splurge?

  1/10/2018

  A look at whether big money and big deals will be in store for 2018.

• Manufacturing Issues Force The FDA To Reject Intarcia's Diabetic Drug Pump

  9/28/2017

• Intarcia Strengthens Board Of Directors For Next Stage Of Growth

  9/20/2017

• New Intarcia Study Evaluates Optimal Way To Switch From Daily Liraglutide Injections To ITCA 650 In Patients With Type 2 Diabetes

  9/15/2017

• Intarcia And Numab AG Reach Key Milestone With Selection Of Multi-Specific Development Candidate For Autoimmune Disease

  9/14/2017

• Fast-Growing Intarcia Awaits Crucial FDA Decision in New Boston HQ

  5/8/2017

• Intarcia Announces FDA Filing Acceptance Of New Drug Application (NDA) For ITCA 650 For The Treatment Of Type 2 Diabetes

  2/6/2017

• Intarcia And Calibr Announce Collaboration And In-Licensing Deal Aimed At Delivering A Next Generation Combination Product For Diabetes And Obesity

  1/9/2017

• Bill & Melinda Gates Foundation Sends $140M to Intarcia for HIV Version of Pump

  12/30/2016

• Intarcia Secures Second Close Of The Series EE Equity Financing For An Additional $206M

  12/29/2016